N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 4 ClinicalTrials.gov

PRP for Glenohumeral Osteoarthritis

Sponsor: Hospital for Special Surgery, New York • ClinicalTrials.gov ID: NCT05675527

Registry updated: 2026-10-09
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.

Interventions

  • Low-dose PRP (Biological)
    Injection
  • High-dose PRP (Biological)
    Injection
  • Saline (Other)
    Injection

Eligibility criteria

Inclusion Criteria: * 18-100 years old * Average NRS pain greater than or equal to 5/10 as a direct result of glenohumeral osteoarthritis (any severity: mild, moderate, or severe) and/or chondral lesion or loss * At least 3 months of pain after onset of symptoms that has failed conservative treatments, including physical therapy * MRI of the affected joint * Transient relief of symptoms after a diagnostic intra-articular injection into the joint * Email address or network access Exclusion Criteria: * Inability to hold non-steroidal anti-inflammatory drugs for 2 weeks prior and 1 month after the injection * Prior platelet-rich plasma injection * Steroid injection within 3 months of the initial injection * Hyaluronic acid within 6 months of the initial injection * Involved in workers' compensation or active litigation involving the affected joint * History of Plavix use * Known uncontrolled systemic illness (uncontrolled diabetes, HIV, vasculitis, autoimmune/autoinflammatory disease) * Presence of acute fractures or gross mechanical deformities * Concurrent "uncontrolled" cervical disorders

Conditions

Shoulder Osteoarthritis

Locations

  • Hospital for Special Surgery — New York, New York, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record